Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial

Published:2020-01 Issue:10218 Volume:395 Page:132-141
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Mateos Maria-Victoria,Cavo Michele,Blade Joan,Dimopoulos Meletios A,Suzuki Kenshi,Jakubowiak Andrzej,Knop Stefan,Doyen Chantal,Lucio Paulo,Nagy Zsolt,Pour Ludek,Cook Mark,Grosicki Sebastian,Crepaldi Andre,Liberati Anna Marina,Campbell Philip,Shelekhova Tatiana,Yoon Sung-Soo,Iosava Genadi,Fujisaki Tomoaki,Garg Mamta,Krevvata Maria,Chen Ying,Wang Jianping,Kudva Anupa,Ukropec Jon,Wroblewski Susan,Qi Ming,Kobos Rachel,San-Miguel Jesus

Publisher

Elsevier BV

Subject

General Medicine

Reference19 articles.

1. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2017

2. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Moreau;Ann Oncol,2013

3. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79;Lammerts van Bueren;Blood,2014

4. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma;Overdijk;MAbs,2015

5. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor-mediated cross-linking;Overdijk;J Immunol,2016

Cited by 323 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation;Frontiers in Hematology;2024-09-11

2. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study;Annals of Hematology;2024-09-04

3. The TGFβ type I receptor kinase inhibitor vactosertib in combination with pomalidomide in relapsed/refractory multiple myeloma: a phase 1b trial;Nature Communications;2024-08-27

4. TRIM44, a Novel Prognostic Marker, Supports the Survival of Proteasome-Resistant Multiple Myeloma Cells;Cells;2024-08-26

5. The emerging role of melflufen and peptide-conjugates in multiple myeloma;Current Opinion in Oncology;2024-08-22